Please provide your email address to receive an email when new articles are posted on . A universal model predicted CV events for people with and without baseline atherosclerotic CVD. Some patients ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibition demonstrated benefit in the broader primary prevention population for LDL lowering and plaque ...

The results may "reflect the fact that once a patient had an ASCVD event, they are subsequently well treated with secondary prevention medications such as antiplatelet agents and lipid-lowering ...

Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 ...

Both women and men with atherosclerotic cardiovascular disease (ASCVD) who take aspirin as secondary prevention fare just as well, for the most part, whether they’re on 81 mg or 325 mg daily, ...